title: IL-3 augments TCR-mediated responses of type 2 CD4 T cells.
abstract: A subset of type 2, but not type 1, CD4 T cell clones expresses IL-3R and can be stimulated by IL-3. Expression of IL-3R on these type 2 T cell clones is induced by TCR stimulation, and subsequent stimulation by IL-3 augmented the proliferation of and IL-4 production by these cells. This augmented response is inhibited by anti-IL-4 mAb, suggesting the involvement of IL-4 in this response. In place of TCR stimulation, treatment of these type 2 CD4 T cell clones with PMA rendered them responsive to further stimulation of proliferation by IL-3, indicating the cooperation between the IL-3R-elicited signals and PKC-mediated signals in stimulating proliferation. Although the augmentation of the TCR-mediated proliferative response by IL-3 was mainly due to the increased production of IL-4, we also demonstrated the presence of IL-4-independent mechanism mediating the response to IL-3. In situ, we found that splenic T cells could be induced to respond to Il-3 by TCR stimulation. Thus, IL-3 can stimulate a specific population of T cells and influence the immune response.
authors.affiliation: Department of Immunology, Faculty of Medicine, University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Dan
authors.forename: Y
authors.initials: Y
authors.lastname: Katakura
authors.forename: A
authors.initials: A
authors.lastname: Ametani
authors.forename: S
authors.initials: S
authors.lastname: Kaminogawa
authors.forename: Y
authors.initials: Y
authors.lastname: Asano
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000941:Antigens / Q000276:immunology; D001667:Binding, Competitive; D002147:Calmodulin / Q000502:physiology; D002999:Clone Cells; D004357:Drug Synergism; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D007377:Interleukin-3 / Q000276:immunology / Q000494:pharmacology*; D015847:Interleukin-4 / Q000096:biosynthesis / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D011948:Receptors, Antigen, T-Cell / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D016185:Receptors, Interleukin-3 / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology; D013154:Spleen; D016559:Tacrolimus / Q000494:pharmacology; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000941:Antigens; D002147:Calmodulin; D007375:Interleukin-1; D007377:Interleukin-3; D011948:Receptors, Antigen, T-Cell; D016185:Receptors, Interleukin-3; D015847:Interleukin-4; D016559:Tacrolimus